Radionuclide Drug Conjugates:China's 15-Year Research and Development Process and Latest Policy Support
10.12290/xhyxzz.2024-0577
- VernacularTitle:放射性核素偶联药物:中国15年研发进程及最新政策支持
- Author:
Dan LIU
1
;
Xiuqi LI
;
Shupeng LIU
;
Xiaofei WU
;
Mengyang YU
;
Hongyun WANG
Author Information
1. 中国医学科学院北京协和医院临床药理研究中心国家药监局药物临床研究与评价重点实验室创新药物临床PK/PD北京市重点实验室,北京 100730;中国医学科学院北京协和医院疑难重症及罕见病国家重点实验室,北京 100730;沈阳药科大学生命科学与生物制药学院,沈阳 110000
- Publication Type:Journal Article
- Keywords:
radionuclide drug conjugates;
peptide-radionuclide conjugates;
antibody-radionuclide conjugates;
radionuc-lide targeted therapy;
status of clinical research and development;
drugs under development in China
- From:
Medical Journal of Peking Union Medical College Hospital
2025;16(4):847-854
- CountryChina
- Language:Chinese
-
Abstract:
Radionuclide drug conjugates(RDC)represent the culmination of interdisciplinary integra-tion.By virtue of their precise targeting capability,high diagnostic sensitivity,and remarkable therapeutic effi-cacy in tumor diagnosis and treatment,RDC has emerged as promising theranostic agents with immense applica-tion potential.This article systematically reviews the progress in RDC development in China from 2009 to 2024,encompassing an overview of RDC,its structure and classification,trends in clinical research,advances in clinical trials,and national policy support.The aim is to provide valuable insights for researchers in related fields,thereby facilitating further development and application of RDC-based therapeutics.
